New treatments for myotonic dystrophy type 1

Who could benefit from this research

What this research studies

This research focuses on developing small molecule therapeutics for myotonic dystrophy type 1 (DM1), a genetic disorder caused by mutations in the DMPK gene. The team has created a screening method to identify compounds that can specifically target and modulate the harmful RNA produced by the mutated gene, without affecting the normal gene function. In initial tests, they found a promising compound that showed potential in reversing disease symptoms in both patient cells and animal models. The goal is to discover and refine additional compounds that can effectively treat DM1.

Why it matters

Where this research is happening

• University of Southern California
  Los Angeles, United States Active

Researchers

• Principal investigator: Comai, Lucio — University of Southern California
• Study coordinator: Comai, Lucio

Related research

Other NIH-funded projects on the same topics.

• New small molecule therapeutics to help myotonic dystrophy

  A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.

  NIH research State University of New York at Albany · Albany, United States · NIH-11617693

• Mechanisms of muscle disease in myotonic dystrophy type 1

  This project looks at why skeletal muscles weaken and waste away in adults with myotonic dystrophy type 1 and aims to uncover the underlying molecular causes.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11597907

• Extracellular vesicle biomarkers to monitor DM1 using urine and blood samples

  A study looking for easy, noninvasive biomarkers in urine and blood to track disease activity in people with myotonic dystrophy type 1.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11494099

• Calcium Channel Blocker in DM1: Can amlodipine help myotonic dystrophy type 1

  This study tests whether the calcium‑channel blocker amlodipine can improve symptoms and survival in myotonic dystrophy type 1 (DM1).

  NIH research University of Rochester · Rochester, United States · NIH-11444061

• Preparing therapies for DM1 across ages, with a focus on children

  A broad, patient-focused effort to bring promising DM1 therapies to both children and adults by enriching trial readiness, biomarkers, and natural history data.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11423652

• Biological factors that drive variability in myotonic dystrophy

  This grant explores why myotonic dystrophy can look very different from person to person by studying its genetic changes and how they affect muscle in adults.

  NIH research University of Florida · Gainesville, United States · NIH-11404431

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.